What’s new in breast cancer research? – July-August 2025
Breast cancer is the second cancer-related cause of death in women worldwide, therefore it is no
Breast
How breast cancer organoids can accelerate ongoing clinical trials and mAb/ADC development under FDA’s animal-reduction roadmap
Introduction Microphysiological systems (MPS) are fast becoming a cornerstone of FDA-aligned non-clinical strategy, especially when paired
Organoid and artificial intelligence in breast cancer research
Introduction Organoid and artificial intelligence approaches are central to the FDA’s roadmap for reducing animal use
Adipose tissue and breast cancer: decoding proximal crosstalk in 3D model
Introduction Adipose tissue-breast cancer crosstalk is emerging as a key driver of tumor initiation, progression, and
3D Breast Cancer Microenvironment: From Organoids to Organ‑on‑Chip for Understanding the TME
Introduction Following our articles on how breast cancer organoids and breast‑cancer‑on‑chip platforms expand beyond conventional 2D and
2D vs 3D breast cancer models: Patient‑derived organoids elevate tumor modeling
3D breast cancer models are rapidly redefining how we investigate the world’s deadliest malignancy in women,
Animal Testing Landscape 2025
About this white paper Animal testing has played a crucial role in medical advancements, leading to
Co-culture With Human Breast Adipocytes Differentially Regulates Protein Abundance in Breast Cancer Cells
Introduction In postmenopausal women, fat mass and adipose-tissue mass (see Human Breast Adipocytes) are closely linked to obesity
Breast Biopsy: Advantages and Challenges for Ex Vivo Culturing in the Age of Personalized Medicine
Breast Biopsies and Breast Cancer Breast cancer is the most common female cancer worldwide with the
get in touch
Get the best insights about Cherry Biotech by Email
Let’s stay in touch!